SCAP and metabolic dysfunction-associated steatotic liver disease: In summary, we demonstrate that METTL3-mediated m6A modification of SCAP rewires cholesterol metabolism to impair CD8+ T cell antitumor response, thereby promoting NAFLD-HCC growth.